Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Oct;28(4):467–472. doi: 10.1128/aac.28.4.467

Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections.

P Van der Auwera, J Klastersky, J P Thys, F Meunier-Carpentier, J C Legrand
PMCID: PMC180285  PMID: 3907494

Abstract

A total of 101 patients with proven Staphylococcus aureus infection were included in a double-blind, placebo-controlled study; this study compared oxacillin (12 g/day, intravenously) or vancomycin (2 g/day, intravenously) plus rifampin (1,200 mg/day, orally) with oxacillin or vancomycin plus placebo. We evaluated 65 patients. Of the patients tested, 33 received oxacillin plus rifampin (13 bacteremias), and 32 received oxacillin plus placebo (16 bacteremias). Clinical cure was achieved in 61% of the patients treated with oxacillin plus rifampin and in 56% of the patients treated with oxacillin plus placebo. Improvement was noted in 27 and 25%, respectively, and failure occurred in 9 and 18%, respectively. These differences were not statistically significant. Bacteriological failure occurred in 3 and 28%, respectively (P less than 0.05). None of the failures within the rifampin-treated group was associated with the emergence of a rifampin-resistant mutant. The rates of superinfection were similar in both groups. The geometric means of the serum bactericidal activity after 1, 6, and 11 h were, respectively, 22, 17, and 9 after treatment with oxacillin plus rifampin and 25, 3.4, and 2.3 after treatment with oxacillin plus placebo. It was suggested that the addition of rifampin to oxacillin or vancomycin might only be beneficial to severely ill patients.

Full text

PDF
467

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acocella G., Hamilton-Miller J. M., Brumfitt W. Can rifampicin use be safely extended? Evidence for non-emergence of resistant strains of Mycobacterium tuberculosis. Lancet. 1977 Apr 2;1(8014):740–742. doi: 10.1016/s0140-6736(77)92179-1. [DOI] [PubMed] [Google Scholar]
  2. Bennett J. V., Brodie J. L., Benner E. J., Kirby W. M. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol. 1966 Mar;14(2):170–177. doi: 10.1128/am.14.2.170-177.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ezer G., Soothill J. F. Intracellular bactericidal effects of rifampicin in both normal and chronic ganulomatous disease polymorphs. Arch Dis Child. 1974 Jun;49(6):463–466. doi: 10.1136/adc.49.6.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Faville R. J., Jr, Zaske D. E., Kaplan E. L., Crossley K., Sabath L. D., Quie P. G. Staphylococcus aureus endocarditis. Combined therapy with vancomycin and rifampin. JAMA. 1978 Oct 27;240(18):1963–1965. doi: 10.1001/jama.240.18.1963. [DOI] [PubMed] [Google Scholar]
  5. Harwick H. J., Weiss P., Fekety F. R., Jr Application of microtitration techniques to bacteriostatic and bactericidal antibiotic susceptibility testing. J Lab Clin Med. 1968 Sep;72(3):511–516. [PubMed] [Google Scholar]
  6. Kerry D. W., Hamilton-Miller J. M., Brumfitt W. Trimethoprim and rifampicin: in vitro activities separately and in combination. J Antimicrob Chemother. 1975 Dec;1(4):417–427. doi: 10.1093/jac/1.4.417. [DOI] [PubMed] [Google Scholar]
  7. Mandell G. L. Interaction of intraleukocytic bacteria and antibiotics. J Clin Invest. 1973 Jul;52(7):1673–1679. doi: 10.1172/JCI107348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Mandell G. L. The antimicrobial activity of rifampin: emphasis on the relation to phagocytes. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S463–S467. doi: 10.1093/clinids/5.supplement_3.s463. [DOI] [PubMed] [Google Scholar]
  9. Mandell G. L., Vest T. K. Killing of intraleukocytic Staphylococcus aureus by rifampin: in-vitro and in-vivo studies. J Infect Dis. 1972 May;125(5):486–490. doi: 10.1093/infdis/125.5.486. [DOI] [PubMed] [Google Scholar]
  10. Massanari R. M., Donta S. T. The efficacy of rifampin as adjunctive therapy in selected cases of staphylococcal endocarditis. Chest. 1978 Mar;73(3):371–375. doi: 10.1378/chest.73.3.371. [DOI] [PubMed] [Google Scholar]
  11. Moorman D. R., Mandell G. L. Characteristics of rifampin-resistant variants obtained from clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 1981 Dec;20(6):709–713. doi: 10.1128/aac.20.6.709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Peard M. C., Fleck D. G., Garrod L. P., Waterworth P. M. Combined rifampicin and erythromycin for bacterial endocarditis. Br Med J. 1970 Nov 14;4(5732):410–411. doi: 10.1136/bmj.4.5732.410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Reller L. B., Stratton C. W. Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests. J Infect Dis. 1977 Aug;136(2):196–204. doi: 10.1093/infdis/136.2.196. [DOI] [PubMed] [Google Scholar]
  14. Sabath L. D., Garner C., Wilcox C., Finland M. Susceptibility of Staphylococcus aureus and Staphylococcus epidermidis to 65 antibiotics. Antimicrob Agents Chemother. 1976 Jun;9(6):962–969. doi: 10.1128/aac.9.6.962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Solberg C. O., Hellum K. B. Protection of phagocytosed bacteria against antimicrobial agents. Scand J Infect Dis Suppl. 1978;(14):246–250. [PubMed] [Google Scholar]
  16. Van der Auwera P., Klastersky J. In vitro study of the combination of rifampin with oxacillin against Staphylococcus aureus. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S509–S514. doi: 10.1093/clinids/5.supplement_3.s509. [DOI] [PubMed] [Google Scholar]
  17. Van der Auwera P., Meunier-Carpentier F., Klastersky J. Clinical study of combination therapy with oxacillin and rifampin for staphylococcal infections. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S515–S522. doi: 10.1093/clinids/5.supplement_3.s515. [DOI] [PubMed] [Google Scholar]
  18. Van der Auwera P., Thys J. P., Meunier-Carpentier F., Klastersky J. The combination of oxacillin with rifampicin in staphylococcal infections: a review of laboratory and clinical studies of the Institut Jules Bordet. J Antimicrob Chemother. 1984 Jun;13 (Suppl 100):31–42. doi: 10.1093/jac/13.suppl_c.31. [DOI] [PubMed] [Google Scholar]
  19. Zinner S. H., Lagast H., Klastersky J. Antistaphylococcal activity of rifampin with other antibiotics. J Infect Dis. 1981 Oct;144(4):365–371. doi: 10.1093/infdis/144.4.365. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES